β-catenin S45F mutation results in apoptotic resistance

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Wnt/β-catenin signaling is vital for embryogenesis and homeostasis, but its deregulation drives carcinogenesis.
• Mutations in CTNNB1 exon 3 are linked to aggressive phenotypes and therapeutic tolerance in various cancers.
• Desmoid tumors, characterized by stable genomes and β-catenin mutations, serve as a model for studying these alterations.

Purpose of the Study:

• To investigate the impact of β-catenin S45F mutations on apoptosis.
• To identify key regulators involved in apoptosis inhibition in these mutants.
• To explore potential therapeutic strategies targeting the identified regulatory mechanisms.

Main Methods:

• Cellular assays to assess apoptosis induction in β-catenin S45F mutants.
• Analysis of RUNX3 expression and its role in regulating apoptosis.
• Investigating potential feedback loops between CTNNB1 and RUNX3.

Main Results:

• β-catenin S45F mutants exhibit deregulated apoptosis with decreased induction.
• RUNX3 was identified as a critical factor inhibiting apoptosis in these mutants.
• Restoring RUNX3 function overcomes apoptosis inhibition, suggesting it as a therapeutic target.
• Evidence suggests a feedback loop where CTNNB1 S45F downregulates RUNX3 expression.

Conclusions:

• The CTNNB1 S45F mutation impairs apoptosis, driven by RUNX3's inhibitory role.
• RUNX3 is a potential therapeutic target for malignancies with this specific mutation.
• A novel feedback loop between CTNNB1 S45F and RUNX3 may offer additional therapeutic avenues for Wnt/β-catenin-driven cancers.